recombinant wnt11 protein (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
94
Structured Review
R&D Systems
recombinant wnt11 protein
Recombinant Wnt11 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant wnt11 protein/product/R&D Systems
Average 94 stars, based on 15 article reviews
Recombinant Wnt11 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant wnt11 protein/product/R&D Systems
Average 94 stars, based on 15 article reviews
recombinant wnt11 protein - by Bioz Stars,
2026-05
94/100 stars
Images
1) Product Images from "Wnt11 mediates fibroblast–smooth muscle cell interaction to promote neurogenic bladder fibrosis in rats"
Article Title: Wnt11 mediates fibroblast–smooth muscle cell interaction to promote neurogenic bladder fibrosis in rats
Journal: Communications Biology
doi: 10.1038/s42003-026-09647-2
Figure Legend Snippet: a Relative mRNA level of WNT11 in fibrotic bladders following BPNI and SCI ( n = 8). Western blotting of WNT11 expression in BPNI ( b ) and SCI ( c )-induced NB. Representative photomicrographs showed that WNT11 (green) was increased in rats after BPNI ( d ) and SCI ( e ). Scale bar = 400 μm. Protein levels of fibroblasts differentiation-related markers (α-SMA and Col-1) in BFs isolated from rats treated with BPNI ( f ) and SCI ( g ). Representative western blotting showing the phenotypic transformation of SMCs (SMTN and MYH10) in BPNI ( h ) and SCI ( i ) rats. Western blotting analyses showing protein levels of WNT11 and markers of fibroblastic differentiation (α-SMA and Col-1) and SMCs phenotypic transformation (SMTN and MYH10) in BFs ( j ) and SMCs ( k ) treated with TGF-β1 at different doses, respectively. Data are shown as the mean ± SD, and P values were determined by the one-way ANOVA followed by Tukey’s post-hoc test ( a ), * P < 0.05, ** P < 0.01.
Techniques Used: Western Blot, Expressing, Isolation, Transformation Assay
Figure Legend Snippet: a – n Eight-week-old male Sprague–Dawley rats were subjected to sham, BPNI, or SCI operation. Vehicle, WNT11, or LGK974 were administered to rats every day after the surgical procedure for 2 weeks, and these rats were euthanized at post 4 weeks of operation. a Schematic of the experimental protocol and treatment regimen. b Representative bladder images in rats treated with vehicle, WNT11, or LGK974 post BPNI or SCI. Representative images of cystometrograms in rats after BPNI ( c ) or SCI ( d ). Statistical results for the intravesical pressure in rats after BPNI ( e ) or SCI ( f ) ( n = 5). Histological analysis of the Masson’s trichrome staining in bladders after BPNI ( g ) or SCI ( h ). Scale bar = 200 μm. Quantifications of detrusor thickness ( i , j ) and collagen content ( k , l ) by Masson’s trichrome staining were performed to assess the bladder fibrosis ( n = 5). Western blotting showing the protein levels of WNT11 and markers of fibroblastic differentiation (α-SMA and Col-1) and SMCs phenotypic transformation (SMTN and MYH10) in bladders after BPNI ( m ) or SCI ( n ). Western blotting analyses showing protein levels of TGF-β1 and markers of fibroblastic differentiation (α-SMA and Col-1) and SMCs phenotypic transformation (SMTN and MYH10) in BFs ( o ) and SMCs ( p ) treated with WNT11 at different doses. Western blotting analyses showing siWNT11 transfection inhibiting fibroblastic differentiation and SMCs phenotypic transformation in BFs ( q ) and SMCs ( r ) with TGF-β1 treatment, respectively. Data are shown as the mean ± SD, and P values were determined by the two-way ANOVA followed by Tukey’s post-hoc test ( e , f , i – l ), ns = not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
Techniques Used: Staining, Western Blot, Transformation Assay, Transfection
Figure Legend Snippet: Representative western blotting and quantitative analyses for FZD10 and Vangl2 in bladders after BPNI ( a ) or SCI ( b ) ( n = 6). Interaction between endogenous WNT11 and Vangl2 in BFs ( c ) and SMCs ( d ). e Confocal microscopy analysis of BFs and SMCs showing the colocalization of WNT11 (red) and Vangl2 (green). Scale bar = 20 μm. Quantification of colocalization was ascertained by ImageJ software in five randomly chosen fields. Numbers in the images correspond to the average Pearson’s correlation coefficient ± SD. Representative Western blotting and summarized data showing the relative protein levels of Vangl2 and markers of fibroblastic differentiation (α-SMA and Col-1) and SMCs phenotypic transformation (SMTN and MYH10) in BFs ( f ) and SMCs ( g ) ( n = 4). Data are shown as the mean ± SD. P values were determined by the two-tailed unpaired Student’s t -test ( a , b ) and the two-way ANOVA followed by Tukey’s post-hoc test ( f , g ), * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
Techniques Used: Western Blot, Confocal Microscopy, Software, Transformation Assay, Two Tailed Test
Figure Legend Snippet: Representative western blotting and quantitative analyses for the phosphorylation levels of JNK and c-JUN in bladders after BPNI ( a ) or SCI ( b ) ( n = 3). BFs ( c ) and SMCs ( d ) developed higher expression levels of p-JNK and p-c-JUN upon WNT11 treatment as indicated by the western blotting and quantitative analyses ( n = 4). Representative immunofluorescence staining and quantitative analyses showing that WNT11 treatment increased the fluorescence intensity and accumulation of p-c-JUN in the nucleus of BFs ( e ) and SMCs ( f ) ( n = 4). Scale bar=100μm. Protein levels of p-JNK, p-c-JUN, and markers of fibroblastic differentiation (α-SMA and Col-1) and SMCs phenotypic transformation (SMTN and MYH10) in BFs ( g ) and SMCs ( h ) treated with WNT11 with or without SP600125 by western blotting ( n = 3). Data are shown as the mean ± SD. P values were determined by the two-way ANOVA followed by Tukey’s post-hoc test ( a , b , g , h ) and the two-tailed unpaired student’s t -test ( c – f ), * P < 0.05, ** P < 0.01, *** P < 0.001.
Techniques Used: Western Blot, Phospho-proteomics, Expressing, Immunofluorescence, Staining, Fluorescence, Transformation Assay, Two Tailed Test
Figure Legend Snippet: Relative mRNA levels of DVL1, DVL2, and DVL3 in fibrotic bladders at 4 weeks after BPNI ( a ) and SCI ( b ) ( n = 6). Representative western blotting and quantitative analyses for the protein levels of DVL1, DVL2, and DVL3 in bladders after BPNI ( c ) or SCI ( d ) ( n = 6). e Representative western blotting and quantitative analyses revealing the protein levels of DVL2 and markers of fibroblastic differentiation, and the phosphorylation levels of JNK and c-JUN in BFs ( n = 3). f Protein levels of p-c-JUN, p-JNK, DVL2, SMTN, and MYH10 in SMCs treated with WNT11 and/or siDVL2 ( n = 3). Immunoprecipitation demonstrated that DVL2 bound to Vangl2 in BFs ( g ) and SMCs ( h ). Representative western blotting showing the presence of the target proteins (input) and immunoprecipitation showing the interaction of Flag-DVL2, Flag-DEP, Flag-DIX, and Flag-PDZ with endogenous Vangl2 in HEK293T cells using antibodies to Flag ( i ) and IgG ( j ). Data are shown as the mean ± SD. P values were determined by the two-tailed unpaired Student’s t -test ( a – d ) and the two-way ANOVA followed by Tukey’s post-hoc test ( e , f ), * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
Techniques Used: Western Blot, Phospho-proteomics, Immunoprecipitation, Two Tailed Test
Figure Legend Snippet: Under the condition of bladder denervation, the WNT11/Vangl2 signal was transmitted into the cytoplasm via DVL2, followed by activating PCP signaling to promote fibroblastic differentiation and SMC phenotypic transformation, which also depended on the interaction of TGF-β1/Smad2/3 signaling at the level of cytomembrane and nucleus, eventually resulting in NB fibrosis.
Techniques Used: Transformation Assay
